(PRWEB) October 16, 2014
The Eye Machine, LLC today announced the signing of an agreement providing Eye Machine Canada the exclusive rights to market the company’s non-invasive treatment for macular degeneration. This agreement is expected to provide The Eye Machine a cash flow in excess of $30 million USD over the first ten years following FDA trial completion and approval from both licensing and royalty fees. The Company will also seek CE Mark approval in Canada upon FDA approval in the United States. The Eye Machine will retain sole rights to commercialize their technology in the United States and other International markets.
About Eye Machine Canada:
Eye Machine Canada was formed by Mr. Justin Sather, Co-Founder of Magen David Meds, a successful online pharmacy with international operations prior to its acquisition, and Dr. Brent Saik, of the Alberta Sports Vision Institute, who have access to a network of over 200 eye physicians in Canada that will provide treatments to their existing patients upon market launch.
About The Eye Machine:
The Eye Machine, LLC was formed to develop, manufacture, and lease to medical professionals, primarily optometrists, a medical device to treat macular degeneration by condensing current from direct current barriers in order to deliver energy around the eye, mitigating the effects of age-related macular degeneration and diabetic retinopathy.
The Eye Machine’s BioCurrent Therapy represents a new, non-invasive treatment for all forms of macular degeneration. The BioCurrent ranges have very specific frequencies to stimulate the desired physiologic response at the retinal level. This low current has been shown by studies to stimulate the production of the active transport enzyme, adenosine triphosphate (“ATP”), which facilitates the movement of nutrition from the blood to the cell. According to recent studies, it improves permeability of the blood vessel membranes and cells, allows better oxygen and nutrition delivery to the cells, metabolism, and removal of by-products from the cells. Through these mechanisms, BioCurrent therapy improves retinal pigment epithelium (“RPE”) efficiency and in so doing may restore and/or improve retinal function.